25 Leading Companies in the Targeted Protein Degradation Market

The global targeted protein degradation market is projected to reach USD 9.85 billion by 2035 from an estimated USD 0.48 billion in 2025, at a CAGR of 35.4% from 2025 to 2035. The rapid growth of this market is being driven by increasing demand for precision medicine, rising investments in oncology drug discovery, technological advancements in PROTACs and molecular glues, and growing collaborations between biotechnology firms and pharmaceutical companies. Targeted protein degradation has emerged as a revolutionary therapeutic approach capable of eliminating disease-causing proteins that were previously considered undruggable.

The market is witnessing strong momentum as pharmaceutical companies continue expanding their research capabilities and clinical pipelines focused on protein degradation technologies. Innovations in ubiquitin-proteasome pathways, lysosome-targeting approaches, and AI-driven drug discovery are expected to further accelerate market expansion during the forecast period.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is one of the leading participants in the targeted protein degradation market, leveraging its extensive oncology expertise and strategic collaborations to develop innovative degrader therapies. The company has invested heavily in next-generation therapeutic technologies capable of targeting previously undruggable proteins involved in cancer progression and immune disorders. Bristol-Myers Squibb continues to strengthen its research capabilities through partnerships with biotechnology innovators and academic institutions, enabling faster development of precision medicine therapies. Its strong global commercial infrastructure and experience in oncology drug development position the company as a key contributor to the expansion of the targeted protein degradation market.

The Menarini Group

The Menarini Group is steadily expanding its presence in advanced therapeutics through investments in oncology research and precision medicine technologies. The company is exploring targeted protein degradation approaches to improve therapeutic efficacy and overcome drug resistance in difficult-to-treat cancers. Menarini’s growing focus on innovative drug discovery and biologics supports its long-term strategy of strengthening its oncology portfolio. By integrating emerging degrader technologies into its research pipeline, the company aims to participate in the growing demand for next-generation cancer therapies.

Arvinas

Arvinas is widely recognized as a pioneer in the targeted protein degradation market and among the first companies to successfully advance PROTAC-based therapies into clinical development. The company focuses on creating oral small-molecule degraders for oncology and neurodegenerative diseases. Arvinas has established major partnerships with global pharmaceutical companies to accelerate clinical trials and commercialization activities. Its innovative PROTAC platform enables selective degradation of disease-causing proteins rather than merely inhibiting them, making it one of the most influential players in the targeted protein degradation industry.

BeOne Medicines

BeOne Medicines is strengthening its role in the targeted protein degradation market through advanced oncology research and innovative therapeutic development programs. The company is actively exploring degrader technologies for hematologic malignancies and solid tumors with the goal of improving treatment outcomes and addressing drug-resistant cancer pathways. Its expanding R&D capabilities and global research collaborations support the development of precision medicines targeting complex disease mechanisms. The company’s growing presence in oncology innovation positions it as an emerging participant in the protein degradation ecosystem.

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. is a leading biotechnology company specializing in targeted protein modulation and degradation technologies. The company utilizes deep expertise in E3 ligase biology and the ubiquitin-proteasome system to develop therapies targeting cancer and immune disorders. Nurix has established multiple strategic partnerships with major pharmaceutical firms to accelerate clinical development and broaden therapeutic applications. Its proprietary platform enables highly selective degradation of disease-driving proteins, helping position the company as a major innovator in the targeted protein degradation market.

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is one of the fastest-growing biotechnology firms focused entirely on targeted protein degradation technologies. The company develops oral small-molecule degraders targeting immunology, inflammation, and oncology indications. Kymera’s robust clinical pipeline and advanced degrader platforms have attracted strategic collaborations with leading pharmaceutical companies. The company’s research efforts are focused on creating therapies capable of delivering improved selectivity, reduced toxicity, and long-lasting therapeutic responses compared to traditional treatment approaches.

C4 Therapeutics, Inc.

C4 Therapeutics, Inc. develops highly selective targeted protein degraders using its proprietary TORPEDO platform. The company focuses on discovering therapies for hematologic cancers and solid tumors through precision protein degradation mechanisms. C4 Therapeutics collaborates with global pharmaceutical companies to expand its research programs and accelerate clinical development. Its innovative approach aims to selectively eliminate disease-causing proteins while minimizing off-target effects, making it an important contributor to the advancement of degrader therapeutics.

AstraZeneca

AstraZeneca is actively investing in targeted protein degradation technologies as part of its broader precision medicine and oncology strategy. The company is integrating degrader research into its oncology pipeline to target proteins associated with resistant cancers and complex disease pathways. AstraZeneca’s strong expertise in biologics, genomics, and oncology drug discovery supports the rapid development of innovative degrader therapies. Through strategic collaborations and internal R&D initiatives, the company continues expanding its role in next-generation therapeutic development.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd is strengthening its presence in the targeted protein degradation market through investments in oncology, neuroscience, and precision medicine research. The company is exploring innovative degrader approaches to improve treatment specificity and address challenging therapeutic targets. Roche’s global expertise in diagnostics and targeted therapies provides a strong foundation for integrating protein degradation technologies into future drug discovery programs. Its growing interest in molecular biology and advanced therapeutic platforms positions the company among the leading pharmaceutical innovators in this field.

Bayer AG

Bayer AG is advancing targeted protein degradation technologies through strategic collaborations and innovative drug discovery initiatives. The company is exploring degrader-based approaches for oncology, cardiovascular diseases, and chronic conditions. Bayer’s investments in precision medicine and next-generation therapeutic platforms support its long-term strategy of developing highly targeted treatments with improved clinical outcomes. Its expanding R&D activities in protein degradation continue to strengthen its presence in the global market.

Captor Therapeutics

Captor Therapeutics specializes in small-molecule targeted protein degradation technologies focused on oncology and autoimmune diseases. The company develops proprietary degrader platforms designed to selectively eliminate disease-causing proteins with improved therapeutic precision. Captor Therapeutics is contributing to Europe’s growing influence in the targeted protein degradation industry through innovative research programs and expanding clinical activities. Its focus on novel therapeutic targets positions the company as an emerging innovator in degrader drug development.

Ranok Therapeutics Co. Ltd.

Ranok Therapeutics Co. Ltd. is rapidly emerging as an important participant in the targeted protein degradation market through its oncology-focused research and innovative degrader technologies. The company is developing therapies aimed at difficult-to-treat cancers and resistant tumor pathways. Ranok Therapeutics is also contributing to the expansion of targeted protein degradation research in the Asia-Pacific region through strategic partnerships and growing R&D investments.

Pfizer Inc.

Pfizer Inc. is actively expanding its capabilities in targeted protein degradation through strategic collaborations, licensing agreements, and internal research programs. The company’s strong expertise in oncology, immunology, and precision medicine supports the development of innovative degrader-based therapeutics. Pfizer’s global commercial reach and large-scale drug development infrastructure provide significant advantages for accelerating the adoption of protein degradation therapies across multiple therapeutic areas.

Novartis AG

Novartis AG is investing heavily in advanced drug discovery technologies, including targeted protein degradation, to strengthen its precision medicine pipeline. The company is exploring innovative degrader approaches for oncology, immunology, and rare diseases. Novartis combines expertise in genomics, biologics, and AI-driven research to accelerate the discovery of next-generation therapeutic solutions. Its continued focus on innovative treatment platforms supports its position as a key player in the evolving targeted protein degradation market.

Foghorn Therapeutics

Foghorn Therapeutics leverages its expertise in chromatin biology to develop targeted protein degradation therapies for genetically determined diseases and cancers. The company focuses on selectively targeting chromatin regulatory systems that drive tumor growth and disease progression. Its innovative therapeutic platforms are designed to address highly complex disease mechanisms that are difficult to treat with conventional therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is advancing molecular glue degrader technologies designed to selectively eliminate disease-driving proteins. The company utilizes advanced chemistry and precision medicine strategies to create therapies targeting oncology and autoimmune diseases. Monte Rosa’s proprietary discovery platform supports the development of highly selective degraders with improved therapeutic profiles and expanded clinical applications.

Biotheryx, Inc.

Biotheryx, Inc. develops small-molecule targeted protein degraders focused on cancer and immune-related disorders. The company’s proprietary technologies support the discovery of therapies capable of addressing challenging therapeutic targets through selective protein elimination. Biotheryx continues to expand its research programs and clinical development activities within the growing targeted protein degradation market.

Cullgen

Cullgen specializes in developing orally bioavailable targeted protein degraders and molecular glue therapeutics. The company leverages its expertise in ubiquitin-proteasome biology to create therapies targeting oncology and inflammatory diseases. Cullgen’s proprietary degrader platform enables the identification of highly selective therapeutic candidates designed to improve treatment efficacy and safety.

Neomorph

Neomorph focuses on discovering molecular glue therapeutics capable of degrading previously inaccessible disease targets. The company combines computational biology, medicinal chemistry, and AI-driven research to accelerate the discovery of novel degraders. Neomorph’s innovative platform aims to expand the therapeutic potential of targeted protein degradation technologies across multiple disease areas.

Lycia Therapeutics

Lycia Therapeutics specializes in lysosomal-targeting chimera technologies that enable the degradation of extracellular and membrane-bound proteins. This innovative therapeutic approach significantly expands the scope of targeted protein degradation beyond traditional intracellular targets. The company’s research efforts are focused on developing therapies for oncology, autoimmune disorders, and other complex diseases.

Photys Therapeutics

Photys Therapeutics develops advanced targeted protein degradation technologies focused on improving selectivity, therapeutic effectiveness, and clinical outcomes. The company’s research programs target oncology and rare diseases using precision degrader platforms designed to eliminate disease-causing proteins with greater specificity.

Plexium, Inc.

Plexium, Inc. utilizes proprietary screening and discovery technologies to identify highly selective targeted protein degraders. The company’s therapeutic programs focus on oncology and neurodegenerative diseases through innovative approaches capable of targeting previously inaccessible proteins. Plexium’s platform supports the rapid identification and optimization of novel degrader candidates.

Seed Therapeutics, Inc.

Seed Therapeutics, Inc. combines AI-driven drug discovery technologies with targeted protein degradation research to accelerate therapeutic development. The company focuses on identifying novel degraders for cancer and chronic diseases using advanced computational and molecular biology tools. Its innovative approach supports faster and more efficient discovery of next-generation therapies.

Avilar Therapeutics, Inc.

Avilar Therapeutics, Inc. pioneers extracellular protein degradation technologies using lysosome-based therapeutic mechanisms. The company’s innovative approach allows the targeting of proteins that cannot be addressed using traditional intracellular degradation methods. Avilar’s research programs are focused on expanding therapeutic possibilities for cancer, inflammatory diseases, and rare disorders.

Autemera

Autemera is emerging as a promising participant in the targeted protein degradation market through its focus on innovative degrader discovery and precision therapeutic development. The company is exploring advanced approaches for selectively targeting disease-causing proteins associated with oncology and chronic disorders. Its growing research activities reflect the increasing interest of biotechnology startups in next-generation protein degradation technologies.